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OBJECTIVE—NEUROG3 plays a central role in the development
of both pancreatic islets and enteroendocrine cells. Homozygous
hypomorphic missense mutations in NEUROG3 have been recently
associated with a rare form of congenital malabsorptive diarrhea
secondary to enteroendocrine cell dysgenesis. Interestingly, the
patients did not develop neonatal diabetes but childhood-onset
diabetes. We hypothesized that null mutations in NEUROG3
might be responsible for the disease in a patient with permanent
neonatal diabetes and severe congenital malabsorptive diarrhea.
RESEARCH DESIGN AND METHODS—The single coding
exon of NEUROG3 was ampliﬁed and sequenced from genomic
DNA. The mutant protein isoforms were functionally character-
ized by measuring their ability to bind to an E-box element in the
NEUROD1 promoter in vitro and to induce ectopic endocrine cell
formation and cell delamination after in ovo chicken endoderm
electroporation.
RESULTS—Two different heterozygous point mutations in
NEUROG3 were identiﬁed in the proband [c.82G.T (p.E28X)
and c.404T.C (p.L135P)], each being inherited from an unaf-
fected parent. Both in vitro and in vivo functional studies indi-
cated that the mutant isoforms are biologically inactive. In
keeping with this, no enteroendocrine cells were detected in in-
testinal biopsy samples from the patient.
CONCLUSIONS—Severe deﬁciency of neurogenin 3 causes
a rare novel subtype of permanent neonatal diabetes. This ﬁnding
conﬁrms the essential role of NEUROG3 in islet development and
function in humans. Diabetes 60:1349–1353, 2011
P
ermanent neonatal diabetes (PNDM), deﬁned as
diabetes diagnosed within the ﬁrst 6 months of
life, is a rare condition with an estimated in-
cidence of 1 in 260,000 live births (1). PNDM
encompasses a number of different monogenic disorders
(2,3). Despite recent advances in the understanding of the
molecular basis of PNDM, the genetic cause remains to be
identiﬁed in approximately 40% of patients (4).
Pancreas development is coordinated by a complex in-
terplay of signaling pathways and transcription factors that
determine early pancreatic speciﬁcation as well as the
latter differentiation of exocrine and endocrine lineages
(5,6). Developmental abnormalities ranging from pancreas
agenesis and hypoplasia to selective endocrine hypoplasia
have been involved in a minority of cases of PNDM, in-
cluding homozygous or compound heterozygous muta-
tions in six genes: IPF1 (6), PTF1A (7), GLIS3 (8), PAX6
(9), RFX6 (10), and NEUROD1 (11). Genes encoding other
pancreatic transcription factors are thus obvious candi-
dates for PNDM of unknown etiology.
The basic helix-loop-helix (bHLH) transcription factor
NEUROG3 plays a central role in the early speciﬁcation of
the endocrine pancreas. Neurog3-null mice fail to generate
any pancreatic endocrine cells and die of diabetes within
a few days after birth (12). In addition, NEUROG3 controls
the developmental pathway of gut epithelial stem cells
destined to become endocrine cells (13). Homozygous
NEUROG3 missense mutations in humans have been
recently associated with a rare form of congenital mal-
absorptive diarrhea characterized by the lack of enter-
oendocrine cells (enteroendocrine cells dysgenesis or
enteric anendocrinosis) (14). Neonatal diabetes was not
reported, but two of three patients developed diabetes
by the age of 8 years. Further studies suggested that the
mutations were hypomorphic rather than null, and it was
proposed that the residual activity was sufﬁcient to pre-
clude glucose intolerance, at least during the ﬁrst years
of life (15).
We report a patient with compound heterozygous
mutations in NEUROG3 and a novel subtype of permanent
neonatal diabetes associated with severe malabsorptive
diarrhea. Introduction of the mutant proteins to chick
embryonic gut endoderm showed that both mutations
were functional null, supporting the hypothesis that the
severity of the NEUROG3 deﬁciency is reﬂected in the
severity of the b-cell defect and hence the age of pre-
sentation with diabetes.
RESEARCH DESIGN AND METHODS
This study was conducted in accordance with the Declaration of Helsinki and
approved by the local ethics committee. Written informed consent was
obtained from the parents/guardians of the patients.
NEUROG3 gene analysis. The single coding exon of NEUROG3 was PCR-
ampliﬁed in three overlapping fragments, sequenced on an ABI 3730 sequencer
(Applied Biosystems, Warrington, UK), and compared with accession number
NM_020999 using Mutation Surveyor v3.24 (SoftGenetics, State College, PA).
Clinical studies. Intestinal biopsies were obtained by ﬂexible endoscopy.
Immunohistochemical assays for chromogranin A were carried out in formalin-
ﬁxed, parafﬁn-embedded biopsy samples of intestinal tissue using the S-ABC
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BRIEF REPORT(streptavidin–biotin–peroxidase complex) technique and commercially avail-
able antibodies (BioGenex). Archival samples from a 4-year-old child with
nonspeciﬁc GI symptoms (abdominal pain) were used as control samples.
A mixed meal test, consisting of 7 mL/kg Boost HP (Mead-Johnson) ingested
over 2 min, was performed in the proband after an overnight fast. Insulin was
not administered on the morning of the test and parenteral nutrition was
withdrawn 48 h before the test. Venous blood was collected in EDTA with
50 µmol aprotinin (Trasylol, Bayer Pharmaceuticals) per milliliter of blood for
hormonal assays at times 0 and 90 min. C-peptide was measured using
a chemiluminescence immunoassay (Roche Diagnostics). Glucagon was
measured by radioimmunoassay as previously described (16).
A standard oral glucose tolerance test with 75 g of glucose was undertaken
in the parents of the patient after an overnight fast.
Functional studies. The mutant protein isoforms were functionally charac-
terized both in vitro and in vivo. Their ability to bind to an E-box element in the
NEUROD1 promoter was investigated using a luciferase/Renilla reporter as-
say. In ovo electroporation of chicken embryos was used to further charac-
terize the endocrine-inducing activity of wild-type and mutant NEUROG3 (see
Supplementary Methods).
RESULTS
Case report. The proband is a Chilean female of Spanish
descent. She was born to nonconsanguineous parents
at 37 weeks gestation with intrauterine growth retarda-
tion (birth weight 1910 g [23.1 SDS for sex and gestational
age]) and presented with nonprogressive nonketotic mod-
erate hyperglycemia (120–180 mg/dL) on the ﬁrst day of
life. Insulin treatment was started on day 20 because of the
persistence of hyperglycemia in the range 150–250 mg/dL.
She has been on continual insulin since several attempts
to discontinue insulin led to hyperglycemia .200 mg/dL,
even in the face of severe diarrhea (see below). She has
excellent metabolic control on NPH insulin twice a day
plus a rapid-acting analog (lispro) before meals, with HbA1c
usually ,6.5% on insulin doses of 0.4–0.8 U/kg/day.
In addition to diabetes, she developed severe mal-
absorptive diarrhea as soon as signiﬁcant enteral feedings
were introduced. Diarrhea has required long-term mixed
enteral and parenteral nutrition. Discontinuation of par-
enteral nutrition at the age of 2 years led to severe failure
to thrive and ataxia. Brain computed tomography (CT)
scan was normal. Because both resolved after the rein-
troduction of night-time parenteral nutrition, vitamin E
deﬁciency secondary to malabsorption was considered the
most likely cause of her neurologic symptoms. Despite
extensive work-up, the cause of the diarrhea in this patient
remained elusive. Abdominal CT scans repeatedly showed
mild intestinal dilation and a macroscopically normal
pancreas. Fecal elastase concentration was normal. In-
testinal mucosa structure appeared normal after standard
staining with hematoxylin-eosin.
The patient is currently 5 years old. Diarrhea remains
her major problem, and she continues to pass 3 to 4 high-
volume liquid stools daily. She takes regular home diet and
an oral nutritional supplement (Pediasure) and receives
night-time parenteral nutrition three times a week. Both
weight (17.3 kg) and height (107.3 cm) are appropriate for
her age. Her last HbA1c was 6.1%. Her daily insulin
requirements are ;0.8 and 0.4 U/kg per day on days with
and without parenteral nutrition, respectively. Additional
clinical details are in the Supplementary Data.
Molecular genetic ﬁndings. Two heterozygous muta-
tions in NEUROG3 were identiﬁed (Fig. 1A). The mater-
nally inherited c.82G.T mutation introduces a premature
stop codon predicted to produce a truncated protein lack-
ing the bHLH and the transactivation domain (p.E28X). The
paternal c.404T.C mutation results in the substitution of
proline for leucine at position 135 (p.L135P), which lies
toward the end of the bHLH domain of NEUROG3 and is
highly conserved across species (Fig. 1B). These variants
have not been previously reported and were not present in
334 Caucasian control chromosomes.
Clinical studies. After the identiﬁcation of the NEUROG3
mutations, intestinal biopsy samples were reinvestigated
for the presence of enteroendocrine cells. Staining for
chromogranin A revealed a complete absence of enter-
oendocrine cells in both the small bowel and the colon
(Fig. 2). To better characterize the pancreatic function in
the patient, a mixed meal test was performed, which
showed a stimulated C-peptide level at 90 min of 546 pmol/L.
Glucagon concentration was below the detection threshold
of the assay both at fasting and after the mixed meal test.
Both heterozygous parents denied diarrhea or any
other gastrointestinal complaints and had normal glucose
tolerance.
NeuroG3-induced transactivation of a NeuroD1 re-
porter construct. A NeuroD1 promoter-driven luciferase
reporter gene was cotransfected with different NeuroG3
constructs into P19 cells, with SV40-driven renilla as in-
ternal standard (Fig. 3A), as previously reported (15). Wild-
type NeuroG3 activity showed a 10- to 20-fold induction
of Luc/renilla activity, compared with GFP vector alone.
The NeuroG3L135P variant had no detectable activity.
Surprisingly, NeuroG3
E28X was capable of activating the
NeuroD1 reporter, albeit at greatly reduced levels com-
pared with NeuroG3 alone (Fig. 3A). Because a less severe
truncation containing the ﬁrst 124 amino acids is com-
pletely inactive (17), we speculated that overexpression
conditions might lead to reduced ﬁdelity of the introduced
stop codon. However, Western blot analysis with Neurog3
antibodies detected 1 mg wild-type NeuroG3 programmed
nuclear extract but failed to detect 20 mg NeuroG3
E28X
programmed extract so we estimate potential read-through
of the nonsense codon to be less than 5%.
In vivo analysis by in ovo electroporation of chicken
endoderm. Previous studies have shown ectopic endo-
crine cell formation when NeuroG3 is electroporated into
the chicken endoderm at Hamburger and Hamilton (HH)
stage 12–15 (18). Electroporations with wild-type NeuroG3
conﬁrmed delaminating and hormone expressing cells
(Fig. 3B) identiﬁed outside the normal pancreas, whereas
electroporation with nGFP alone had no detectable effect
on the chicken endoderm (Fig. 3B). Electroporation with
NeuroG3
E28X failed to induce any endocrine cells in 6 of
8 embryos, whereas only a minuscule fraction of the total
number of GFP
+ cells expressed glucagon in the remaining
two embryos (Fig. 3B). Such cells, which also are seen oc-
casionally in vector controls, might be the result of electro-
porating cells that were already committed to endocrine fate.
No ectopic endocrine cells were found in the NeuroG3
L135P
variant. We therefore conclude that NeuroG3
L135P has no
activity and NeuroG3
E28X has very limited or no activity.
DISCUSSION
We report the ﬁrst case of PNDM caused by biallelic
NEUROG3 mutations. In keeping with the expression
pattern of NEUROG3, the patient not only presented with
neonatal diabetes but also developed severe diarrhea
secondary to the lack of enteroendocrine cells.
Inactivation of Neurog3 in mice resulted in severe hy-
perglycemia and dehydration soon after birth (12), which
highlights its central role during pancreatic endocrine
speciﬁcation. These knockout mice had a macroscopically
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tiﬁed on standard histological analysis. Furthermore, no
hormone-containing cell could be detected by immuno-
histochemistry. The importance of Neurog3 in the control
of endocrine differentiation can also be seen in the gut,
where all kinds of gastrointestinal cells are derived from
stem cells residing in the base of the intestinal crypts. In
mice, intestinal enteroendocrine cells cannot differentiate
without the expression of Neurog3 (13).
Enteroendocrine cell dysgenesis has previously been
described in three patients with homozygous R93L or
R107S NEUROG3 missense mutations (14). Interestingly,
none presented with neonatal diabetes. However, the two
patients who survived beyond early childhood developed
persistent hyperglycemia by 8 years and were diagnosed
with type 1 diabetes although a detailed characterization
of the diabetic phenotype was not reported. Functional
studies on these mutations revealed that the resulting
protein products were hypomorphic and retained certain
residual activity, which could contribute to precluding
glucose intolerance during the ﬁrst years of life (15). In
addition, it has been proposed that NEUROG3 may dif-
ferentially bind to speciﬁc cofactors in the intestinal and
pancreatic progenitor cells (19).
The lack of detectable glucagon suggests that there are
no a-cells, whereas the detectable C-peptide levels (and
excellent metabolic control) suggest the presence of at
least some b-cells. Neurog3 is required for both a- and
b-cell development in mice, but the two cell types appear
at different stages of embryonic development. Whereas
a-cells appear during a narrow window in the early phase
FIG. 2. Endoscopically resected intestinal mucosa from the patient and
a control subject. Enteroendocrine cells can normally be identiﬁed by
staining the preparation for chromogranin A (left panels). No immu-
nohistochemical reactivity was seen either in the duodenal or in the
colonic tissue from the patient (right panels). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
FIG. 1. A: Electropherograms and family pedigree showing inheritance of NEUROG3 mutations. Squares represent men, and circles represent
women subjects. The black-ﬁlled symbol denotes the patient with neonatal diabetes, and the dot-ﬁlled symbols represent the unaffected het-
erozygous carriers. Genotype is shown underneath each symbol; N denotes the wild-type allele. B: Schematic organization of NEUROG3 protein.
Numbers refer to the amino acids bordering the functional domains. The conservation across species of various residues within or nearby the bHLH
domain is shown. (A high-quality color representation of this ﬁgure is available in the online issue.)
O. RUBIO-CABEZAS AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, APRIL 2011 1351of pancreatic development, b-cells appear later, after the
secondary transition (20). Thus b-cells develop from
a much larger pool of progenitors and in larger numbers. It
is possible that the minute residual activity of NEUROG3
(or an alternative bHLH factor) is capable of sustaining
limited b- but no a-cell formation, because the larger pool
of progenitors available for b-cell development partly com-
pensates for the reduced proendocrine activity of NEUROG3.
Alternatively, a redundant, NEUROG3-independent path-
way may result in the production of at least some b-cells, as
has previously been suggested (19).
This is a rare cause of PNDM. No mutations in NEUROG3
were reported in 13 patients with neonatal or childhood-
onset antibody-negative type 1 diabetes (21) or in an ad-
ditional 35 patients with permanent neonatal diabetes of
unknown cause (unpublished data) (22).
Heterozygous mutations in NEUROD1, encoding an-
other bHLH transcription factor that play a main role in the
development of the endocrine pancreas, have been asso-
ciated with autosomal dominant diabetes (23). This raised
the hypothesis that mutations in NEUROG3 may also lead
to the development of maturity-onset diabetes of the
young (MODY) or late-onset familial diabetes. Two studies
have failed to conﬁrm this (24,25). Both parents in this
study have a heterozygous null mutation in NEUROG3
and normal glucose tolerance (aged 30 and 35 years). It
seems, therefore, unlikely that heterozygous mutations in
NEUROG3 contribute signiﬁcantly to MODY.
In conclusion, our study shows that recessive null
mutations in NEUROG3 may cause a rare form of neonatal
diabetes with intestinal anendocrinosis. This conﬁrms the
important role that NEUROG3 plays in the endocrine
FIG. 3. A: Transactivation of the NEUROD1 promoter by wild-type (WT) and mutant NEUROG3 proteins in P19 cells. E28X activity is reduced to
;25% compared with WT (P < 0.01 using a two-tailed Student t test), whereas L135P does not show activity over the vector control. Surprisingly,
residual activity is seen when comparing E28X with the vector control (P < 0.00002). B: Whole-mount immunohistochemical detection of green
ﬂuorescent protein (GFP; green) and glucagon (red) in chicken embryos electroporated with WT and mutant NEUROG3 plasmids. WT NEUROG3
(B and B’), introduced into FoxA2 expressing endoderm of the prospective duodenum of 13–15 somite chicken embryos, induces the development
of glucagon-expressing endocrine cells that delaminate from the duodenal epithelium, whereas control embryos (A and A’), or embryos expressing
E28X (C and C’) and L135P (D and D’) mutants, do not develop such cells. A, B, C,a n dD show three-dimensional projections of the duodenum
(duo) and dorsal pancreas (dp), whereas A’, B’, C’, and D’ show single optical sections from the same embryos. (A high-quality digital repre-
sentation of this ﬁgure is available in the online issue.)
NEUROG3 MUTATIONS IN NEONATAL DIABETES
1352 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgpancreas in humans and suggests a differential require-
ment for NEUROG3 gene dosage in enteroendocrine de-
velopment versus pancreatic function.
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